Table 6. Summary ORs (95% CI) and value of the heterogeneity of XRCC1 Arg399Gln polymorphism under different genetic models according to studies with a minimum of 200 participants on cancer risk1.
| Variables | No. comparisons(SZ case/control) | Dominant model | Recessive model | Additive model | |||
| OR (95% CI) | P h /I 2 | OR (95% CI) | P h /I 2 | OR (95% CI) | P h /I 2 | ||
| Overall | 263 (91,969/119,090) | 1.03 (1.00–1.06)* | <0.001/51.0% | 1.08 (1.03–1.13)* | <0.001/51.9% | 1.09 (1.04–1.14)* | <0.001/50.9% |
| Cancer type | |||||||
| Bladder cancer | 17 (6,206/7,235) | 1.02 (0.95–1.10) | 0.234/18.8% | 0.88 (0.79–0.98) | 0.396/5.1% | 0.91 (0.81–1.03) | 0.306/13.2% |
| Breast cancer | 49 (29,249/32,281) | 1.04 (0.99–1.09)* | 0.001/43.2% | 1.08 (1.00–1.17)* | <0.001/52.2% | 1.04 (1.00–1.18)* | <0.001/47.8% |
| Cervical cancer | 5 (1,007/1,660) | 2 | 0.003/75.6% | 1.37 (1.03–1.81) | 0.765/0.0% | 1.37 (1.02–1.84) | 0.134/43.1% |
| Colorectal cancer | 20 (7,487/11,838) | 1.04 (0.96–1.14)* | 0.030/40.9% | 1.18 (0.98–1.42)* | <0.001/62.9% | 1.17 (0.97–1.43)* | <0.001/63.7% |
| Esophageal cancer | 13 (3,110/6,149) | 1.00 (0.88–1.13)* | 0.040/45.0% | 1.16 (0.95–1.41)* | 0.065/40.4% | 1.16 (0.92–1.45)* | 0.021/49.9% |
| Gastric cancer | 15 (3,382/7,282) | 1.00 (0.86–1.15)* | 0.002/59.1% | 1.08 (0.94–1.25) | 0.479/0.0% | 1.07 (0.93–1.25) | 0.155/27.3% |
| Hepatocellular cancer | 6 (1,398/2,015) | 1.35 (1.05–1.75)* | 0.035/58.4% | 1.19 (0.92–1.54) | 0.952/0.0% | 1.39 (1.03–1.86) | 0.954/0.0% |
| Head and neck cancer | 36 (8,308/12,035) | 0.99 (0.91–1.07)* | 0.002/45.3% | 0.95 (0.84–1.08)* | 0.025/34.3% | 0.95 (0.83–1.10)* | 0.006/41.3% |
| Leukemia | 11 (2,027/2,525) | 1.18 (0.97–1.42)* | 0.012/55.8% | 1.07 (0.89–1.29) | 0.236/21.7% | 1.17 (0.88–1.55)* | 0.058/43.8% |
| Lymphoma | 3 (794/1,362) | 1.12 (0.93–1.34) | 0.887/0.0% | 1.16 (0.86–1.57) | 0.575/0.0% | 1.23 (0.90–1.69) | 0.672/0.0% |
| Pancreatic cancer | 4 (1,204/2,135) | 0.99 (0.86–1.15) | 0.145/44.4% | 1.03 (0.83–1.29) | 0.635/0.0% | 1.03 (0.81–1.30) | 0.349/8.8% |
| Prostate cancer | 17 (4,387/4,388) | 1.03 (0.88–1.21)* | <0.001/62.6% | 1.20 (0.98–1.46)* | 0.019/47.1% | 1.18 (0.97–1.43)* | 0.069/36.9% |
| Skin cancer | 11 (4,680/5,354) | 0.99 (0.91–1.07) | 0.489/0.0% | 0.95 (0.84–1.07) | 0.127/33.9% | 0.94 (0.83–1.07) | 0.218/23.7% |
| Lung cancer | 29 (10,512/12,692) | 0.96 (0.89–1.03)* | 0.078/28.5% | 1.01 (0.93–1.10) | 0.105/26.3% | 0.99 (0.87–1.12)* | 0.071/30.2% |
1
All summary ORs were calculated using fixed-effects models. In the case of significant heterogeneity (indicated by *), ORs were calculated using random-effects models.
The bold values indicate that the results are statistically significant.